Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944815 | 0.92 | MAPT (0.41) | RAB9ANPC1CYP3A4MRGPRX4MAPT | |
| SCHEMBL4946956 | 0.91 | MAPT (0.41) | RAB9ANPC1CYP3A4MRGPRX4MAPT | |
| SCHEMBL4945300 | 0.91 | CYP3A4 (0.41) | RAB9ANPC1CYP3A4MRGPRX4MAPT | |
| SCHEMBL4943814 | 0.91 | NR4A2 (0.44) | RAB9ANPC1CYP3A4MRGPRX4MAPT | |
| SCHEMBL4946301 | 0.91 | CYP3A4 (0.39) | RAB9ANPC1CYP3A4MRGPRX4MAPT | |
| SCHEMBL4948201 | 0.90 | CYP3A4 (0.39) | RAB9ANPC1CYP3A4MRGPRX4MAPT | |
| SCHEMBL4946950 | 0.89 | MRGPRX4 (0.42) | RAB9ACYP3A4MRGPRX4MAPTLMNA | |
| SCHEMBL4946321 | 0.89 | MAPT (0.40) | RAB9ACYP3A4MRGPRX4MAPTLMNA | |
| SCHEMBL4942407 | 0.88 | CYP3A4 (0.40) | RAB9ANPC1CYP3A4MRGPRX4MAPT | |
| SCHEMBL4945312 | 0.88 | MRGPRX4 (0.43) | RAB9ACYP3A4MRGPRX4MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513803-B1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | GALDERMA RES & DEV (FR) | 2008-06-18 | — | — | EP | disclosed |
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
| EP-1513803-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101945-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | RAB9A 1437/4885NPC1 3016/4885CYP3A4 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.